Boost Biopharma


Boost Biopharma provides partners with potent, durable, and broadly neutralizing combinatorial antigens (and proprietary sequences for mRNA vaccines). Boost has developed a complete library of SARS-CoV-2 antigens, which have demonstrated exceptional immune responses in mice and non-human primates when administered intramuscularly, intranasally, and with a variety of adjuvants (and no adjuvants, as well). Our Rapid Antigen Deployment process enables us to generate new antigens that are ready for testing within 14-21 days from sequence identification. Our team also generates novel broadly neutralizing monoclonal antibodies, including the recent development of a broadly neutralizing SARS-CoV-2 mAb (XBB.1.5 binding at 1.1 picomolar) that is currently available for evaluation and license. Boost also works with partners to develop custom antigens and improve our partners' existing candidates.